Biosion

Executive Summary

Biosion is a global biotechnology company headquartered in Nanjing, China, with additional R&D centers in the United States. Founded in 2017, the company focuses on discovering and developing transformative antibody therapies for oncology and immunology. Biosion leverages its proprietary H³ antibody discovery platform to generate diverse, high-affinity therapeutic candidates, including bispecific antibodies and other novel modalities. The company's pipeline spans preclinical to phase 2 clinical stages, with several candidates targeting key pathways in cancer and autoimmune diseases. As a private entity with 200-500 employees, Biosion has positioned itself as a player in the rapidly evolving biotech landscape, though its financials and specific valuation remain undisclosed.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead bispecific antibody in oncology60% success
• Q2 2026IND filing for next-generation immunology asset70% success
• TBDPotential partnership or licensing deal for H³ platform50% success